Skip to main content

Table 1 Baseline characteristics of approved patients enrolled in Italy in the avelumab MCC EAP

From: Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program

Characteristic n = 102
Age
 Median (range), years 70.6 (41.0–92.0)
 < 65, n (%) 27 (26.5)
 ≥ 65, n (%) 75 (73.5)
Sex, n (%)
 Female 23 (22.5)
 Male 78 (76.5)
 Data missing 1 (1.0)
ECOG PS, n (%)
 0 52 (51.0)
 1 30 (29.4)
 2 4 (3.9)
 3 1 (1.0)
 Data missing 15 (14.7)
Line of therapy, n (%)
 1 1 (1.0)
 ≥ 2 101 (99.0)
  1. EAP expanded access program, ECOG PS Eastern Cooperative Oncology Group performance status, MCC Merkel cell carcinoma